Novavax Inc NVAX:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:04 AM EDT
203.00quote price arrow up+0.91 (+0.45%)
Volume
717
Close
202.09quote price arrow up+0.75 (+0.37%)
Volume
1,807,456
52 week range
16.41 - 331.68

...

Loading . . .
  • Open202.11
  • Day High207.23
  • Day Low195.77
  • Prev Close202.09
  • 52 Week High331.68
  • 52 Week High Date02/09/21
  • 52 Week Low16.41
  • 52 Week Low Date05/01/20

Key Stats

  • Market Cap14.926B
  • Shares Out73.86M
  • 10 Day Average Volume2.66M
  • Dividend-
  • Dividend Yield-
  • Beta1.47
  • YTD % Change81.23

KEY STATS

  • Open202.11
  • Day High207.23
  • Day Low195.77
  • Prev Close202.09
  • 52 Week High331.68
  • 52 Week High Date02/09/21
  • 52 Week Low16.41
  • 52 Week Low Date05/01/20
  • Market Cap14.926B
  • Shares Out73.86M
  • 10 Day Average Volume2.66M
  • Dividend-
  • Dividend Yield-
  • Beta1.47
  • YTD % Change81.23

RATIOS/PROFITABILITY

  • EPS (TTM)-6.79
  • P/E (TTM)-29.78
  • Fwd P/E (NTM)10.38
  • EBITDA (MRQ)-415.734M
  • ROE (MRQ)-189.60%
  • Revenue (MRQ)475.60M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-87.94%
  • Debt To Equity (MRQ)74.61%

EVENTS

  • Earnings Date05/08/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates...
James Young Ph.D.
Chairman
Stanley Erck
President
Rick Crowley
Chief Operating Officer
Gregory Covino
Chief Financial Officer
Ben Machielse
Executive Vice President
Address
21 Firstfield Rd
Gaithersburg, MD
20878-1757
United States